458:
326:
Fischer, William; Eron, Joseph J.; Holman, Wayne; Cohen, Myron S.; Fang, Lei; Szewczyk, Laura J.; Sheahan, Timothy P.; Baric, Ralph; Mollan, Katie R.; Wolfe, Cameron R.; Duke, Elizabeth R.; Azizad, Masoud M.; Borroto-Esoda, Katyna; Wohl, David A.; Loftis, Amy James; Alabanza, Paul; Lipansky, Felicia;
274:
Imran, Mohd.; Kumar Arora, Mandeep; Asdaq, Syed
Mohammed Basheeruddin; Khan, Shah Alam; Alaqel, Saleh I.; Alshammari, Mohammed Kanan; Alshehri, Mohammed M.; Alshrari, Ahmed Subeh; Mateq Ali, Alreshidi; Al-Shammeri, Ahmed Muteb; Alhazmi, Bushra Dhuhayyan; Harshan, Aishah Ali; Alam, Md. Tauquir; Abida,
85:
partnered with
Ridgeback to perform clinical trials with Molnupiravir in humans to treat COVID-19. Ridgeback has also developed a number of other advanced medications such as monoclonal antibody Ansuvimab against the Ebola virus.
76:
130:
526:
227:"Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19"
507:
401:
79:. The complaint alleged that Ridgeback lobbied the government for millions in funding to help develop Molnupiravir.
151:
428:
531:
500:
65:
57:
56:, where the drug was initially developed with $ 16 million in grants from Federal agencies including the
277:"Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19"
493:
481:
60:. The terms of the deal were undisclosed. Molnupiravir was initially researched as a treatment for
103:
38:
333:
225:
Painter, George R.; Natchus, Michael G.; Cohen, Oren; Holman, Wendy; Painter, Wendy P. (2021).
37:
Ridgeback is privately owned by hedge fund manager and physician, Wayne Holman (formerly of
328:
42:
48:
In early 2020, Ridgeback purchased an exclusive license for the commercial development of
41:) and his wife Wendy Holman. Wendy is the CEO at the company, which refers to itself as a
8:
375:
303:
276:
251:
226:
202:
177:
379:
367:
349:
308:
256:
207:
327:
Painter, Wendy P. (2021). "Molnupiravir, an Oral
Antiviral Treatment for COVID-19".
473:
432:
402:"Hedge fund manager stands to profit on 'flip' of taxpayer-funded coronavirus drug"
359:
354:
298:
288:
246:
238:
197:
189:
104:"Hedge fund manager stands to profit on 'flip' of taxpayer-funded coronavirus drug"
53:
152:"Drug launched at Emory reduces virus that causes COVID-19 to undetectable levels"
406:
242:
108:
477:
469:
363:
193:
82:
23:
293:
520:
27:
371:
312:
260:
211:
49:
72:
30:
company, primarily known for its involvement in developing a successful
131:"Breakthrough Ebola Treatment Receives Contract from U.S. Government"
61:
31:
465:
429:"Emory's DRIVE, Ridgeback partnering for drug vs coronavirus"
350:"COVID antiviral pills: what scientists still want to know"
457:
71:
Ridgeback was mentioned in a whistleblower complaint from
273:
224:
133:(Press release). Ridgeback Biotherapeutics. 2 April 2020
325:
77:
Biomedical
Advanced Research and Development Authority
518:
501:
218:
508:
494:
332:
302:
292:
250:
201:
399:
347:
169:
527:Health care companies based in Florida
519:
319:
400:Rowland, Christopher (25 June 2020).
452:
144:
101:
348:Ledford, Heidi (10 November 2021).
267:
175:
13:
14:
543:
456:
68:activity against other viruses.
421:
393:
341:
123:
95:
16:American biotechnology company
1:
334:10.1101/2021.06.17.21258639v1
89:
58:National Institutes of Health
43:majority woman owned business
480:. You can help Knowledge by
476:corporation or company is a
243:10.1016/j.coviro.2021.06.003
102:Crow, David (30 June 2020).
7:
231:Current Opinion in Virology
178:"Ansuvimab: First Approval"
10:
548:
451:
364:10.1038/d41586-021-02783-1
194:10.1007/s40265-021-01483-4
294:10.3390/molecules26195795
75:, former director of the
20:Ridgeback Biotherapeutics
39:S.A.C. Capital Advisors
532:Medical company stubs
464:This article about a
176:Lee, Arnold (2021).
489:
488:
431:(Press release).
539:
510:
503:
496:
474:biotechnological
460:
453:
444:
443:
441:
440:
433:Emory University
425:
419:
418:
416:
414:
397:
391:
390:
388:
386:
345:
339:
338:
336:
323:
317:
316:
306:
296:
271:
265:
264:
254:
222:
216:
215:
205:
173:
167:
166:
164:
163:
158:. March 17, 2021
156:Emory University
148:
142:
141:
139:
138:
127:
121:
120:
118:
116:
99:
54:Emory University
547:
546:
542:
541:
540:
538:
537:
536:
517:
516:
515:
514:
449:
447:
438:
436:
435:. 23 March 2020
427:
426:
422:
412:
410:
407:Washington Post
398:
394:
384:
382:
346:
342:
324:
320:
272:
268:
223:
219:
174:
170:
161:
159:
150:
149:
145:
136:
134:
129:
128:
124:
114:
112:
109:Financial Times
100:
96:
92:
83:Merck & Co.
64:, but may have
17:
12:
11:
5:
545:
535:
534:
529:
513:
512:
505:
498:
490:
487:
486:
470:pharmaceutical
461:
446:
445:
420:
392:
340:
318:
275:Abida (2021).
266:
217:
188:(5): 595–598.
168:
143:
122:
93:
91:
88:
66:broad spectrum
15:
9:
6:
4:
3:
2:
544:
533:
530:
528:
525:
524:
522:
511:
506:
504:
499:
497:
492:
491:
485:
483:
479:
475:
471:
467:
462:
459:
455:
454:
450:
434:
430:
424:
409:
408:
403:
396:
381:
377:
373:
369:
365:
361:
357:
356:
351:
344:
335:
330:
322:
314:
310:
305:
300:
295:
290:
286:
282:
278:
270:
262:
258:
253:
248:
244:
240:
236:
232:
228:
221:
213:
209:
204:
199:
195:
191:
187:
183:
179:
172:
157:
153:
147:
132:
126:
111:
110:
105:
98:
94:
87:
84:
80:
78:
74:
69:
67:
63:
59:
55:
51:
46:
44:
40:
35:
33:
29:
28:biotechnology
25:
21:
482:expanding it
463:
448:
437:. Retrieved
423:
411:. Retrieved
405:
395:
383:. Retrieved
353:
343:
321:
287:(19): 5795.
284:
280:
269:
234:
230:
220:
185:
181:
171:
160:. Retrieved
155:
146:
135:. Retrieved
125:
113:. Retrieved
107:
97:
81:
70:
50:Molnupiravir
47:
36:
34:medication.
19:
18:
73:Rick Bright
521:Categories
439:2021-12-01
413:1 December
385:1 December
162:2021-11-07
137:2021-12-01
115:1 December
90:References
380:238529450
281:Molecules
237:: 17–22.
62:influenza
372:34625735
313:34641339
261:34271264
212:33751449
32:COVID-19
466:medical
329:medRxiv
304:8510125
252:8277160
203:7983082
26:-based
378:
370:
355:Nature
331:
311:
301:
259:
249:
210:
200:
376:S2CID
182:Drugs
52:from
24:Miami
22:is a
478:stub
415:2021
387:2021
368:PMID
309:PMID
257:PMID
208:PMID
117:2021
472:or
360:doi
299:PMC
289:doi
247:PMC
239:doi
198:PMC
190:doi
523::
468:,
404:.
374:.
366:.
358:.
352:.
307:.
297:.
285:26
283:.
279:.
255:.
245:.
235:50
233:.
229:.
206:.
196:.
186:81
184:.
180:.
154:.
106:.
45:.
509:e
502:t
495:v
484:.
442:.
417:.
389:.
362::
337:.
315:.
291::
263:.
241::
214:.
192::
165:.
140:.
119:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.